Clinical Trials Logo

Clinical Trial Summary

This study plans to detect the presence of trastuzumab by mass spectroscopy in relapsed posterior fossa ependymoma (PFEPN) tumor specimen pre-treated with a single dose of intrathecal (IT) trastuzumab, as well as to evaluate toxicity of intrathecal trastuzumab in combination with subcutaneous (subQ) Granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with relapsed PFEPN


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02774421
Study type Interventional
Source University of Colorado, Denver
Contact Melissa Widener, PA
Phone 720-777-4349
Email melissa.widener@childrenscolorado.org
Status Recruiting
Phase Phase 1
Start date December 2016
Completion date March 2026